Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability

Advanced derivatives of the Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) have shown therapeutic efficacy upon topical administration in animal models of asthma and dermatitis. Here, we studied the plasma stability of the EPI-X4 lead compounds WSC02 and JM#21, using mass spectrometry to monitor the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Alfonso, Armando, Heck, Astrid, Ruiz-Blanco, Yasser Bruno, Gilg, Andrea, Ständker, Ludger, Kuan, Seah Ling, Weil, Tanja, Sanchez-Garcia, Elsa, Wiese, Sebastian, Münch, Jan, Harms, Mirja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735595/
https://www.ncbi.nlm.nih.gov/pubmed/36499357
http://dx.doi.org/10.3390/ijms232315029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735595/
https://www.ncbi.nlm.nih.gov/pubmed/36499357
http://dx.doi.org/10.3390/ijms232315029

Ejemplares similares